Home ›
Multiple Myeloma Trials ›
NCT07760454
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.
Trial Details
NCT ID NCT07760454
Phase PHASE1 / PHASE2
Sponsor UCARsgen Biotech Limited
Status RECRUITING
Cancer Type Multiple Myeloma
Interventions
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538 Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
Voluntarily participate in the trial; fully understand and sign the informed consent form (ICF); willing and able to comply with all trial procedures. Age ≥ 18 years, male or female. Patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least 3 prior lines of therapy, including at least one proteasome … Relapsed/refractory disease defined per IMWG 2016 response criteria,.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →